Connect with us at upcoming industry events: DCAT Week  |  BIO Europe  |  GCSG. Learn more.

Who We Are

Our Mission to Improve Lives

Estimates show that nearly 2 billion people around the world lack access to essential medicines. At Tanner Pharma Group , we’re advocates for the lifesaving power of medicine. But beyond this, we understand the importance of having access to it. Through our global partner network, determined and resourceful team, decades of global distribution experience and passion for health equity, we’ve been able to positively impact thousands of lives through access to medicine. And our journey is only just beginning. Learn more

Join the Tanner journey. Let’s find ways to improve patient lives, together.

YES, WE CAN

Our goal is simple, to improve lives by increasing access to medicines around the world.

We deliver solutions for organizations in the global healthcare network, removing barriers and implementing programs so they can:

  • Provide access to medicines for patients in need
  • Demonstrate the value of new medications
  • Enable better health

YES, WE WILL

Our commitment is unwavering.

We relentlessly pursue and deliver the best solutions to enable access, no matter how challenging the situation. We are resourceful and creative and always going the extra mile.

YES, WE DID

The Challenge:

Reduce the risk of infection in leukemia patients.

LEUKINE®, approved by the US FDA in 1991, is a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) that stimulates the immune system and has been used in leukemia patients to reduce the risk of infection.

In 2018, Partner Therapeutics, Inc. (PTx) acquired the global rights to develop, manufacture, and commercialize Leukine ® (sargramostim) from Sanofi. As a small company, Ptx did not have the internal resources to handle international requests for the drug and didn’t know how they could successfully support patients outside the US, in full regulatory compliance, even though the product was not registered in other geographies.

 

Read More

YES, WE DID

The Challenge:

Provide free cancer treatment to patients around the world

The Max Foundation is a global non-profit organization focused on increasing the access to treatment, care and support for people living with cancer around the world. In 2017 the Foundation sought to put in place The Max Access Solutions program, a patient-centric care model for delivering free cancer treatment to those in need. The Foundation wanted to be able to offer its patients targeted treatment using a portfolio of oncology medicines from multiple pharmaceutical companies. They sought a partner to handle the distribution, quality assurance and regulatory activities to safely and securely store, handle and deliver the medicines to their patients. After evaluating options for a partner to manage the distribution, Tanner was selected.

Read More

YES, WE DID

The Challenge:

Uninterrupted distribution to patients in Latin America

A major pharmaceutical company divested a mature pipeline asset to a medium size pharma company that did not have a presence in Latin America, but wanted to continue distribution of the product.

Read More

YES, WE DID

The Challenge:

Assuring continuity during a global pandemic

A leading clinical-stage biotechnology company required packs of a comparator to conduct a Phase III trial for their leading asset. They required the stock in a single lot, and because of the ongoing COVID-19 pandemic, wanted stock with a long shelf life and additional assurances regarding the supply chain to minimize lead times and the chance of unexpected manufacturer disruptions.

Read More

TESTIMONIAL

Tanner Pharma Group is truly an example of what it means to put humanity at the center of their business. This was not just words on a page or some empty mission statement, it’s compassion in action!

They are a prime example on how Pharma should be running their business and focusing their motivation.

Joshua Frase Foundation

PROVIDING ACCESS TO

120+

countries with the help of our non-profit collaborators:

PROVIDING ACCESS TO

RECENT NEWS & EVENTS

  1. The Chairman’s Award 2024: Rilee Humphries

    The Chairman’s Award is Tanner’s highest accolade. It is awarded to the associate who goes above and beyond to meet the needs of our team and our partners, and exemplifies our Tanner values of determined and tenacious, resourceful and creative, and responsive and caring to further enable us to pursue our mission to improve patient…

    Read More
  2. Tanner Pharma Directors to Attend Key International Healthcare Conferences in 2024

    Directors from Tanner Pharma Group will attend several international healthcare conferences in the coming weeks. Connect with our team members directly or via conference platforms to schedule meetings. We look forward to meeting with you. JPM Healthcare Conference 8-11 January | San Francisco, CA USA Arab Health 29 January – 1 February | Dubai SCOPE…

    Read More
  3. A Rare Affair 2024  

    The rare disease community is a diverse and resilient group of people who face many challenges in their quest for better health and quality of life. They are not alone in this journey, as they are supported by dedicated and passionate organizations that work tirelessly to develop and deliver innovative therapies for rare genetic diseases.  One of these organizations is Ultragenyx, a biopharmaceutical company focused on the development of novel products…

    Read More

Tanner Pharma Group uses cookies on its website. By continuing to access this website you are agreeing to Tanner Pharma Group’s Data Privacy Policy. For more information, click here.